To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901

NCT06171880 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-12-15

No results posted yet for this study

Summary

To evaluate the safety and pharmacokinetic characteristics after the administration of JC-001 and JLP-1901

Conditions

  • Healthy Adult

Interventions

DRUG

JLP-1901

administration of JLP-1901

DRUG

JC-001(active comparator)

administration of JC-001(tenofovir)

Sponsors & Collaborators

  • Jeil Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2022-03-11
Completion
2022-05-13

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06171880 on ClinicalTrials.gov